Please use this identifier to cite or link to this item: https://doi.org/10.1111/j.1349-7006.2011.02110.x
DC FieldValue
dc.titleAn IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells
dc.contributor.authorUota, S.
dc.contributor.authorZahidunnabi Dewan, M.
dc.contributor.authorSaitoh, Y.
dc.contributor.authorMuto, S.
dc.contributor.authorItai, A.
dc.contributor.authorUtsunomiya, A.
dc.contributor.authorWatanabe, T.
dc.contributor.authorYamamoto, N.
dc.contributor.authorYamaoka, S.
dc.date.accessioned2016-09-06T08:18:53Z
dc.date.available2016-09-06T08:18:53Z
dc.date.issued2012-01
dc.identifier.citationUota, S., Zahidunnabi Dewan, M., Saitoh, Y., Muto, S., Itai, A., Utsunomiya, A., Watanabe, T., Yamamoto, N., Yamaoka, S. (2012-01). An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer Science 103 (1) : 100-106. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1349-7006.2011.02110.x
dc.identifier.issn13479032
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126707
dc.description.abstractAdult T-cell leukemia (ATL) is a fatal T-cell malignancy associated with human T-cell leukemia virus type I infection. The aberrant expression of nuclear factor-κB (NF-κB) is considered to contribute to the malignant phenotype and chemo-resistance of ATL cells. Because of the poor prognosis of ATL, the development of new therapeutic strategies is direly needed. In the present study, we show that an IκB kinase 2 (IKK2) inhibitor, IMD-0354, efficiently inhibits the survival of CD4 +CD25 + primary ATL cells and prevents the growth of or induces apoptosis of patient-derived ATL cell lines. Assays of transcription with integrated forms of reporter genes revealed that IMD-0354 suppresses NF-κB-dependent transcriptional activity. Moreover, the daily administration of IMD-0354 prevents the growth of tumors in mice inoculated with ATL cells. Our results suggest that targeting IKK2 with a small molecule inhibitor, such as IMD-0354, is an attractive strategy for the treatment of ATL. © 2011 Japanese Cancer Association.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1111/j.1349-7006.2011.02110.x
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMICROBIOLOGY
dc.description.doi10.1111/j.1349-7006.2011.02110.x
dc.description.sourcetitleCancer Science
dc.description.volume103
dc.description.issue1
dc.description.page100-106
dc.description.codenCSACC
dc.identifier.isiut000298877600013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

19
checked on Sep 13, 2019

WEB OF SCIENCETM
Citations

19
checked on Sep 13, 2019

Page view(s)

22
checked on Sep 6, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.